Showing results (241-250 of 271) with videos related to
Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2020
Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized TrialIe-Wen Sim, Gelsomina L Borromeo, Claudine Tsao, et al.Dalton Transactions (Cambridge, England : 2003)|September 21, 2005
Primary amido substituted diborane4 compounds and imidodiborate4 anionsR Angharad Baber, Jonathan P H Charmant, Alistair J R Cook, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2026
Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung CancerAbigail R Barber, Richard S Edwards, Sofia N Dos Santos, et al.European Journal of Nuclear Medicine and Molecular Imaging|December 25, 2019
The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancerMeghana Kulkarni, Simon Hughes, Andrew Mallia, et al.Journal of Thoracic Imaging|July 13, 2015
Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity AnalysisConnie Yip, Nunzia Tacelli, Martine Remy-Jardin, et al.Radiology|March 31, 2026
Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung CancerRobert O'Shea, Carolyn Horst, Thubeena Manickavasagar, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 6, 2024
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of 99mTc and 188Re Theranostic Agents for Prostate CancerTruc T Pham, Ingebjørg N Hungnes, Charlotte Rivas, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 31, 2009
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group StudyJ W Sweetenham, B Goldman, M L LeBlanc, et al.European Radiology|February 22, 2024
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancerDaniel Johnathan Hughes, Eleni Josephides, Robert O'Shea, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 20, 2021
A Phase II, Open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: The PRONOUNCED studyAsim Afaq, Heather Payne, Reena Davda, et al.Pageof 28